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Abstract
Background: Nitric oxide (NO) regulates renal proximal tubular (PT) Na+ handling through
modulation of Na+-K+ ATPase. Peroxisome Proliferator Activated Receptorα (PPARα), a nuclear
transcription factor, is expressed in PTs and has been reported to influence NO generation/activity
in renal tissues. This study tested the hypothesis that PPARα interacts with NO and thereby affects
renal tubular Na+ transport. Urinary excretion of nitrite (UNOXV) and Na+ (UNaV) and PT Na+
transport (Na+-K+ ATPase activity) were determined in rats treated with clofibrate (250 mg/kg i.p)
or WY14643 (45 mg/kg; i.p.), a PPARα ligand, 2% NaCl (orally), clofibrate/NaCl, L-NAME, an
inhibitor of NO production (100 mg/kg; orally), L-NAME/Clofibrate.
Results: Clofibrate or WY14643 increased PPARα expression by 106 ± 7% (p < 0.05) and 113 ±
8% (p < 0.05), respectively. Similarly, clofibrate and WY14643 increased expression of MCAD, a
downstream target protein of PPARα by 123 ± 8% (p < 0.05) and 143 ± 8% (p < 0.05), respectively.
L-NAME attenuated clofibrate-induced increase in PPARα expression by 27 ± 2% (p < 0.05) but
did not affect MCAD expression. UNOXV excretion increased 3–4 fold in rats treated with
clofibrate, WY14643 or NaCl from 44 ± 7 to 170 ± 15, 144 ± 18 or 132 ± 11 nmol/24 hr,
respectively (p < 0.05). Similarly, clofibrate, WY14643 or NaCl elicited a 2–5 fold increase in UNaV.
L-NAME significantly reduced basal UNOXV and UNaV and abolished the clofibrate-induced
increase. Clofibrate, WY14643, NaCl or clofibrate + NaCl treatment reduced Na+-K+-ATPase
activity in the PT by 89 ± 23, 62 ± 10, 43 ± 9 and 82 ± 15% (p < 0.05), respectively. On the contrary,
L-NAME or ODQ, inhibitor of sGC, abolished the inhibition of Na+-K+-ATPase activity by
clofibrate (p < 0.05). Clofibrate either alone or with NaCl elicited ~2-fold increase in the
expression of the α1 subunit of Na+-K+ ATPase in the PT while L-NAME abolished clofibrate-
induced increase in Na+-K+ ATPase expression.
Conclusion:  These data suggest that PPARα activation, through increased NO generation
promotes renal excretion of Na+ through reduced Na+-K+ ATPase activity in the PT probably via
post translational modification of Na+-K+-ATPase.
Background
The proximal tubule (PT) is a major player in the mainte-
nance of salt and water hemostasis as it accounts for the
absorption of approximately 70% Na+ and water-filtered
load [1]. The PT epithelial cells are highly enriched in Na+-
K+ ATPase that is located at the basolateral domain of
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epithelial cells and provides the driving force for active
sodium and potassium translocation and for the second-
ary active transport of other solutes across the renal
tubules. It consists of α (α1-α4), β (β1-β3) and γ (γ1 & γ2)
subunits of which the α1 isoform represents the major
Na+-transporting system [2]. In different species and tis-
sues, the renal Na+-K+ ATPase activity is regulated tightly
by complex multi hormonal mechanisms and intracellu-
lar second messengers to maintain plasma electrolytes
during dietary and pathological fluctuation of electrolytes
and pH [1,3]. Such regulation involves the activation of
distinct hormone- and tissue-specific intracellular signal-
ing molecules such as protein kinase C (PKC) and protein
kinase A (PKA) [4,5].
Nitric oxide (NO) is a key paracrine and autocrine regula-
tor of physiological function in a number of organs
including the kidney and NO has been reported to inhibit
the α1 isoform of Na+-K+ ATPase in the PT probably via
activation of PKC, or by inhibition of PKA [6-8]. The three
isoforms of NO synthase (NOS) enzyme are differentially
expressed throughout the kidney with the iNOS isoform
expressed in the PT accounting for NO production in this
segment [9-11].
Peroxisome Proliferator Activated Receptors (PPARs) con-
stitute a subfamily of the nuclear receptor super-family
which are activated by natural ligands such as fatty aids
and eicosanoids [12-14]. PPARs regulate gene expression
through binding with retinoic acid receptor (RXR) to spe-
cific DNA sequence elements termed PPAR response ele-
ments (PPREs) or by interfering with other transcription
factor pathways in a DNA binding-independent manner
[15,16]. Of the three PPARs, namely PPARα, β and γ, only
the PPARα stimulates the β-oxidative degradation of fatty
acids, resulting in high yield of ATP production and play-
ing an essential role in supporting kidney reabsorptive
functions [17,18]. Fatty acid β-oxidation occurs in the kid-
ney peroxisomes which are found exclusively in the PT of
the nephron and ranks among the largest peroxisomes
known in different cell types [19,20]. PPARα is highly
expressed in the rat kidney PT as well as in other nephron
segments but its functional role remains unclear [21,22].
Based on the co-expression of PPARα and iNOS in the PT
and the fact that PPARα activation modulates the produc-
tion of NO in non renal cells, we tested the hypothesis
that PPARα activators regulate renal tubular Na+ transport
by modulating PT Na+-K+-ATPase activity via NO produc-
tion [23].
In this study, we employed NaCl loading as a stimulant
for NO production [24] and investigated the effect of clof-
ibrate and WY14643, PPARα activators, on renal NO pro-
duction and Na+-K+ ATPase activity in the freshly isolated
renal proximal tubular cells of the rat.
Results
Fifty five age and weight-matched male Sprague-Dawley
rats were used in this study. Initial body weights of the
animals were 194 ± 6, 191 ± 3, 198 ± 4, 195 ± 3, 201 ± 3,
199 ± 4, and 199 ± 6 g for the control, clofibrate, NaCl,
clofibrate/NaCl, L-NAME, Clofibrate/L-NAME and
WY14643 groups, respectively. After the treatment, body
weights were unchanged except in the control group
where the weight slightly increased by 12 ± 1 % (p < 0.05)
to 218 ± 6 g.
PPARα and MCAD protein expression
The effects of treatment with different agents on PPARα
and MCAD protein expression are illustrated in Fig. 1. Fig.
1a shows that, treatment with clofibrate or WY14643 for
7 days increased PPARα expression by 106 ± 7% (p <
0.05) or 113 ± 8% (p < 0.05), respectively. L-NAME did
not affect basal expression of PPARα but it attenuated
clofibrate-induced increase in PPARα expression (27 ±
2%; p < 0.05). However, PPARα expression in groups
treated with NaCl alone or in combination with clofibrate
was not significantly altered (data not shown). Fig. 1b
shows that clofibrate or WY14643 increased MCAD pro-
tein expression by 123 ± 8% (p < 0.05) or 143 ± 8% (p <
0.05), respectively. Unlike the data obtained with PPARα,
L-NAME was without effect on basal or clofibrate-induced
MCAD expression.
Urinary excretion of Nitrite and Na+
Compared to the control rats, treatment with clofibrate,
WY14643 or NaCl elicited a 3–4 fold increase (p < 0.01)
in 24 hr urinary nitrite excretion rats (Fig. 2a). Combined
administration of clofibrate and NaCl produced an
increase in nitrite excretion that was not greater than that
produced by clofibrate alone. On the other hand, L-NAME
reduced basal nitrite excretion by 46 ± 7% (p < 0.05) and
abolished clofibrate-induced increase in nitrite excretion
(p < 0.05). Accompanying these changes was a 2–5-fold
increase in urinary Na+ excretion (Fig. 2b) following treat-
ment with WY14643, clofibrate or NaCl. L-NAME reduced
24 hr Na+ excretion by 80 ± 14% (p < 0.05) and abolished
clofibrate-induced increase in Na+ excretion (p < 0.05).
Na+-K+ATPase activity and the expression of Na+-
K+ATPase α1 protein
The effects of these treatments on Na+-K+ATPase activity
and expression are illustrated in Fig. 3. Basal Na+-
K+ATPase activity in these experiments was 226 ± 28
nmol/mg protein/min. Clofibrate, NaCl or WY14643
caused a significant reduction in Na+-K+ ATPase activity in
the PT by 89 ± 33% (p < 0.05), 43 ± 4% (p < 0.05) or 63
± 23% (p < 0.05), respectively (Fig. 3a). Combined
administration of clofibrate and NaCl elicited a greater
reduction in Na+-K+-ATPase activity (81 ± 14%, p < 0.05),
that was higher than that produced by NaCl alone but notBMC Pharmacology 2004, 4 http://www.biomedcentral.com/1471-2210/4/1
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Changes in PPARα and MCAD protein expression Figure 1
Changes in PPARα and MCAD protein expression. Expression of PPARα (a) and MCAD (b) proteins in vehicle-treated (Con-
trol) rats, or rats treated for 7 days with clofibrate (Clofibrate; 250 mg/kg; i.p.), L-NAME (L-NAME; 100 mg/kg; p.o.), WY14643 
(WY14643; 45 mg/kg; i.p.), or clofibrate and L-NAME (Clofibrate/L-NAME). The upper tracing in each figure shows a typical 
immunoblot for PPARα (a) or MCAD (b) proteins. Values are mean ± SEM. Values in parentheses are the number of experi-
ments. * p < 0.05 versus Control. #-p < 0.05 versus Clofibrate.BMC Pharmacology 2004, 4 http://www.biomedcentral.com/1471-2210/4/1
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Urinary excretion of nitrite and Na+ Figure 2
Urinary excretion of nitrite and Na+. 24 hr urinary excretion of nitrite (a) and Na+ (b) after 7 days of treatment with vehicle 
(Control), clofibrate (Clofibrate; 250 mg/kg; i.p.), L-NAME (L-NAME; 100 mg/kg; p.o.), 2 % NaCl in drinking water (NaCl), 
WY14643 (WY14643; 45 mg/kg; i.p.), clofibrate and NaCl (Clofibrate/NaCl) or clofibrate and L-NAME (Clofibrate/L-NAME). 
Values in parentheses are the number of animals. Values are mean ± SEM. *-p < 0.05 versus Control. #-p < 0.05 versus 
Clofibrate.BMC Pharmacology 2004, 4 http://www.biomedcentral.com/1471-2210/4/1
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Na+-K+-ATPase activity and Expression of Na+-K+-ATPase α1 protein Figure 3
Na+-K+-ATPase activity and Expression of Na+-K+-ATPase α1 protein. Na+-K+-ATPase activity (a) and expression of Na+-K+-
ATPase α1 protein (b) in the renal proximal tubules of different experimental groups: Control (vehicle-treated), clofibrate 
(clofibrate 250 mg/kg; i.p.), L-NAME (L-NAME; 100 mg/kg; p.o.), Clofibrate/L-NAME (Clofibrate and L-NAME), NaCl (2% NaCl 
in drinking water), Clofibrate/NaCl (clofibrate and NaCl) or WY14643 (WY14643; 45 mg/kg; i.p.). Values are mean ± SEM. Val-
ues in parentheses are the number of animals. *-p < 0.05 versus Ccontrol. #-p < 0.05 versus Clofibrate. @-p < 0.05 versus 
NaCl.BMC Pharmacology 2004, 4 http://www.biomedcentral.com/1471-2210/4/1
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greater than that produced by clofibrate alone. On the
other hand, L-NAME did not affect basal Na+-K+-ATPase
activity but abolished clofibrate-induced reduction in
Na+-K+ATPase activity. The role of cGMP in clofibrate-
induced reduction in Na+-K+-ATPase activity was evalu-
ated by measuring the Na+-K+-ATPase activity in the pres-
ence of ODQ (10-6M), an inhibitor of sGC. ODQ reversed
clofibrate-induced reduction in Na+-K+-ATPase activity
from 25 ± 10 to 58 ± 7 nmol/mg protein/min (data not
shown).
Figure 3b illustrates that treatment with WY14643 or clof-
ibrate elicited a significant increase in the expression of
the α1 subunit of the Na+-K+-ATPase protein, the major
Na+ transporting isoform and this remained elevated even
during combined administration of NaCl and clofibrate.
However, though NaCl its own inhibited Na+-K+ATPase
activity, it did not affect the expression of Na+-K+-ATPase
α1 protein. Similarly, L-NAME alone did not alter Na+-K+-
ATPase α1 expression but abolished clofibrate-induced
increase in Na+-K+-ATPase expression.
Discussion
The main highlight of this study is that activation of
PPARα increased renal NO production and inhibited Na+
transport in freshly isolated PT of the rat. These results
therefore add to a growing list of actions of PPARα which
had until recently being thought were limited to specific
tissue types. The biologic function of PPARα was initially
limited to lipid catabolism and peroxisome proliferation
in the liver [17]. However, with the discovery that PPARα
is present in a variety of different cell types and a growing
list of their activities, their functions and biological effects
have grown tremendously [25].
PPARα is highly expressed in the kidney especially in the
PT cells. Indeed, PPARα-mediated  β-oxidation of long
chain fatty acids occurs predominantly in the S3 segment
of the PT and represents an important mechanism for
energy production in the kidney cortex. In addition, fatty
acid β-oxidation enzymes which exist in the mitochon-
dria, peroxisomes and microsomes of this nephron seg-
ment are very important in the preservation of renal
function following damage to the kidney [26-29]. The
importance of fatty acid β-oxidation and PPARα is also
underscored by the recognition that the kidney is the only
other organ in addition to the liver in which fatty acid β-
oxidation occurs in the peroxisomes which are found
exclusively in the PT of the nephron, and rank among the
largest peroxisomes known in different cell types [20].
The association of PPARα with PT drew us to this nephron
segment with a view to evaluating its effect on ion trans-
port. PT cells possesses an abundance of Na+-K+ ATPase
that regulates transepithelial Na+  movement and a
number of agents, endogenous and exogenous, and dis-
ease conditions can modulate the activity of the enzyme.
Prominent amongst the endogenous regulators of Na+-
K+ATPase activity in the PT is NO. However, the effects of
NO on PT are controversial as increase as well as inhibi-
tion of Na+ transport have been reported [6,30,31].
Following the demonstration in some recent reports that
PPARα ligands modulate NO production in vascular tis-
sues and macrophages, we wondered whether PPARα acti-
vators affect NO production in the kidney and if so,
whether NO plays a role in the effect of PPARα on sodium
excretion and renal Na+ transport in the PT. We first estab-
lished that clofibrate and WY14643 are PPARα ligands
based on their capacity to increase PPARα expression and
its downstream target protein MCAD. These effects were
accompanied by increased nitrite excretion. However, L-
NAME inhibited PPARα but not MCAD expression (Fig.
1). Using NaCl loading as a stimulus for NO production
we observed that NaCl caused a 3–4 fold increase in uri-
nary excretion of nitrite as did clofibrate and WY14643,
prototype PPARα activators [24]. The increase in urinary
nitrite excretion is indicative of the ability to stimulate
renal NO production. In parallel to this, clofibrate,
WY14643 and NaCl decreased Na+-K+-ATPase activity and
the combined administration of clofibrate and NaCl fur-
ther enhanced this reduction. In addition, ODQ, an
inhibitor of sGC, or L-NAME attenuated the effects of clof-
ibrate on Na+-K+ATPase activity. The decrease in Na+-K+-
ATPase activity following sodium loading is in agreement
with studies that demonstrated increased level of endog-
enous digitalis-like factor and is consistent with the
known capacity of the PT Na+-K+-ATPase to participate in
promoting Na+ excretion [32]. Taken together, these data
suggest that PPARα activation affects Na+ transport and
that this effect may involve NO production. This being the
case, it is expected that Na+ and water excretion should
increase when NO production increased. This was indeed
the case as we observed a marked increase in urinary Na+
excretion following administration of WY14643, clofi-
brate or NaCl alone or in combination with each other.
Though NO production was of similar magnitude in the
groups treated with clofibrate, WY14643 or NaCl, the cor-
responding effect on UNaV and urine output is greatest for
the NaCl group. We interpret these data to mean that salt
loading promotes natriuretic and diuretic effects that are
not exclusively linked to NO production in the PT. It thus
appears that high salt concentration may increase the
osmolar gradient in the medulla and countercurrent mul-
tiplier system therein and thereby elicit a strong natriu-
retic effect that involves additional mechanism apart from
NO production. The lower effect on PT Na+-K+ATPase
activity in NaCl-treated group despite the strong natriure-
sis suggests additional effects on other nephron segments
possibly in the loop of Henle where inhibition of Na+, K+BMC Pharmacology 2004, 4 http://www.biomedcentral.com/1471-2210/4/1
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or Cl- transport can produce strong natriuretic effect as
seen with the loop diuretics.
Though there are many isoforms of Na+-K+-ATPase, the α-
1 isoform represents the main sodium transporter in the
basolateral membrane and is the target of many hor-
mones that regulate PT sodium reabsorption [2,32]. In
these experiments, it is note worthy that reduction in Na+-
K+ATPase activity by clofibrate, clofibrate and NaCl, and
WY14643 but not that by NaCl alone was accompanied
by increased expression of α1 subunit of Na+-K+ATPase
protein. Similarly, L-NAME abolished clofibrate-induced
increase in Na+-K+-ATPase expression but not its activity.
We interpret the incongruence in activity and expression
of Na+-K+-ATPase to post translational modifications of
the enzyme by NaCl and L-NAME. The reason for this is
not clear but it is not surprising considering that dissocia-
tion has also been observed between PKC-inhibitable
inhibition by dopamine of Na+-K+-ATPase activity and
phosphorylation of the α subunit of the enzyme [33].
Conclusion
Data presented in this study suggest that PPARα activators
increase NO generation and promote ion transport in the
PT through a reduction in Na+-K+ ATPase activity. The
effects produced by NaCl or L-NAME may involve a post
translational modification of Na+-K+ ATPase.
Methods
This study was approved by the Institutional Animal Care
and Use Committee (IACUC) of Texas Southern Univer-
sity following the National Institutes of Health (NIH)
guidelines for laboratory animal use.
Materials
All chemicals were purchased from Sigma-Aldrich (St.
Louis, MO) unless specified otherwise. Rabbit polyclonal
antibody against Na+-K+ ATPase α1 and PPARα were pur-
chased from Santa Cruz (Santa Cruz Biotechnology, Inc.
Santa Cruz, CA). Antibody to MCAD (medium chain acyl-
dehydrogenase) and 1H-[1,2,4] oxadiazolo [4,3-α] qui-
noxalin-1-one (ODQ) were obtained from Cayman
(Cayman Chemicals, Ann Arbor, MI)
Adult male Sprague-Dawley rats (Harlan, Houston TX),
150–200 g were randomly allocated to 4 treatment groups
as follows: Control (mineral oil, 50 µl i.p.; n = 8), clofi-
brate (250 mg/kg; i.p.; n = 6), NaCl (2% in drinking water;
n = 4), and clofibrate/NaCl (n = 7). The NaCl group was
included since salt loading is a known activator of NO
production [24]. In another set of experiments 30 rats
were randomly divided into five treatment groups (n = 6
in each group): control, clofibrate (250 mg/kg; i.p.), L-
NAME (100 mg/kg; orally) clofibrate/L-NAME and
WY14643 (45 mg/kg; i.p.) a synthetic PPARα ligand. Ani-
mals were maintained on the treatments for 7 days before
they were sacrificed. They were kept in metabolic cages for
collection of 24 hr urine output on days 1 and 7 of the
study period. At the end of the treatment period, animals
were anesthetized with pentobarbital sodium (50 mg/kg;
i.p). and the kidneys were perfused with 20 ml of Krebs
buffer containing iron oxide particles (100 µl/10 ml
buffer).
Isolation of proximal tubule
PT from the rat kidney were isolated following the proce-
dure described by Chibalin et al with little modification.
Kidneys were isolated, cut longitudinally, and the cortex
was separated from the medulla and the papilla [33]. Cor-
tical tissues were minced and placed in scintillation vials
containing 10 ml fresh ice-cold digestion solution (colla-
genase 230 u/ml, hyaluronidase 250 u/ml, trypsin inhib-
itor 10 µg/ml, sucrose 320 mM, and EDTA 0.1 mM).
Using a plastic pipette, the samples were titurated for
about 20 sec to loosen up tissue and to expose more
tubules for digestion. These samples were then incubated
in a shaking water bath for 15–20 min at 37°C while con-
tinuously bubbling with 95% O2 and 5% CO2. After a
complete digestion, samples were placed in a 50 ml cen-
trifuge tube which was placed on a BioMag magnetic sep-
arator (Polyscience Inc, PA). Vascular tissue and glomeruli
containing iron were separated by magnetic attraction and
tubular fraction carefully transferred to another tube.
Proximal tubular fraction was further enriched by percoll
density-gradient centrifugation in which samples were
layered in between 5 ml of 35% percoll and 5 ml of 100%
percoll solution and centrifuged at 13000 g for 15 min.
Proximal tubular fraction was carefully collected. Viability
of the tubules (95%) was confirmed by microscopy and
trypan blue exclusion test.
Na+-K+ ATPase activity assay
Na+-K+ ATPase activity was determined in the proximal
tubular fraction as the rate of inorganic phosphate
released in the presence or absence of ouabain [6,34].
Tubular suspension was washed three times with phos-
phate-free buffer (NaCl 2.36 M, NaHCO3 0.54 M, KCl 0.4
M, MgCl2 0.12 M) and the final proximal tubule suspen-
sion was adjusted to 1 mg protein/ml. Aliquots of tubular
suspension (100 µl) were pipetted into 800 µl reaction
mixture (NaCl 75 mM, KCl 5 mM, MgCl2 5 mM, NaN2 6
mM, Na EGTA 1 mM, imidazole 37.5 mM, Tris HCl 75
mM and histidine 30 mM; pH 7.4) with or without oua-
bain (1 mM) in a final volume of 1 ml and pre-incubated
for 5 min in a water bath at 37°C. Reaction was initiated
by adding Tris ATP (4 mM) and was stopped after 15 min
of incubation at 37°C by adding 50 µl of 50% TCA. For
determination of ouabain-insensitive ATPase activity,
NaCl and KCl were omitted from the reaction mixture
where ouabain was added. To quantify the amount ofBMC Pharmacology 2004, 4 http://www.biomedcentral.com/1471-2210/4/1
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phosphate produced, I ml of coloring reagent (10%
ammonium molybdate in 10 N sulfuric acid + ferrous sul-
fate) was added to the reaction mixture, mixed thoroughly
and centrifuged at 3000 g for 10 min. Formation of phos-
phomolybdate was determined spectrophotometrically at
740 nm against a standard curve prepared from K2HPO4.
Na+-K+ ATPase activity was estimated as the difference
between total ATPase activity and the ouabain-insensitive
ATPase activity and expressed as nmol phosphate pro-
duced per mg protein per min. In another set of experi-
ments, proximal tubules isolated from clofibrate-treated
rats were incubated with ODQ (10-6 M), an inhibitor of
soluble guanylyl cyclase (sGC) for 30 mins before meas-
urement of Na+-K+ ATPase activity.
Immunoblotting of Na+-K+ ATPase α1 protein
Solubilized protein collected from the PT of the rat kidney
was separated in 10% SDS-PAGE gel and transferred to a
PVDF membrane (Amersham Pharmacia, NJ). Blots were
blocked with 5% non-fat dried milk (wt/vol) and 0.1%
Tween 20 in TBS (50 mM Tris Base, 137 mM NaCl, 1 M
HCl; pH 7.4) overnight at 4°C and incubated for 1 hr with
isoform-specific anti α-1 mouse monoclonal antibody
(1:500). After washing in TBST (TBS + 0.1% Tween 20),
blots were incubated with corresponding peroxidase-con-
jugated affinity purified anti-mouse anti serum at 1:1000
dilution for 1 hr. Immunoreactivity was detected by
enhanced chemiluminescence (Hyperfilm ECL, Amer-
sham Pharmacia, NJ).
Immunoblotting of PPARα and MCAD protein
40  µg of protein from PT homogenate was electro-
phoresed on 12% polyacrylamide gels and transferred to
PVDF membrane (Amersham Pharmacia, NJ). Blots were
probed with rabbit polyclonal anti PPARα antibody and
anti MCAD antibody at 1:1000 and 1: 500 dilutions,
respectively, followed by addition of secondary antibody
at 1:5000 dilution. Immunocomplexes were visualized
using an enhanced chemiluminescence (ECL-Plus) detec-
tion system from Amersham Pharmacia, NJ.
The intensity of the bands was scanned and quantified
using Personal Densitometer SI scanner and ImageQuant
analysis software (Molecular Dynamics, Sunnyvale, CA).
Biochemical Analysis
Protein concentration in the tissue preparation was deter-
mined by the BCA protein assay kit from Pierce (Rockford,
IL). Urine Na+  was determined by flame photometer
(PFP7. Genway Ltd, Essex, UK) and urinary excretion of
nitrite was determined colorimetrically by Griess Assay.
Statistical Analysis
Data were presented as mean ± SEM and compared
between groups for significance using students 't' test. In
all cases, p < 0.05 was considered as significant.
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